ProfileGDS5678 / 1460501_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 46% 44% 45% 43% 43% 47% 46% 44% 43% 44% 48% 44% 45% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1178346
GSM967853U87-EV human glioblastoma xenograft - Control 23.0289444
GSM967854U87-EV human glioblastoma xenograft - Control 33.0413545
GSM967855U87-EV human glioblastoma xenograft - Control 42.9471143
GSM967856U87-EV human glioblastoma xenograft - Control 52.9572543
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1923847
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.162446
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0180544
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9815743
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0063844
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.139948
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9768944
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0561745
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.032644